Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 16/20 | 0.55 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14805628 | 0.83 | HCAR2 (0.55) | HCAR2KMT2APARP1 | |
| SCHEMBL18487514 | 0.83 | ALDH1A1 (0.54) | HCAR2 | |
| SCHEMBL6014115 | 0.78 | HCAR2 (0.59) | HCAR2PARP1 | |
| SCHEMBL3826949 | 0.76 | HPGD (0.59) | KMT2A | |
| SCHEMBL11794359 | 0.76 | HCAR2 (0.61) | HCAR2PARP1 | |
| SCHEMBL11781060 | 0.75 | HCAR2 (0.59) | HCAR2PARP1 | |
| SCHEMBL290313 | 0.75 | MAOB (0.62) | KMT2APARP1 | |
| SCHEMBL20954965 | 0.75 | HCAR2 (0.59) | HCAR2PARP1 | |
| SCHEMBL29831694 | 0.75 | MAOB (0.62) | KMT2APARP1 | |
| SCHEMBL10984818 | 0.75 | HCAR2 (0.59) | HCAR2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037059-A1 | GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-09 | — | — | US | disclosed |
| US-9481675-B2 | Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20130079323-A1 | GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037059-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | HCAR2 2341/4885XDH 137/4885KMT2A 2823/4885 |
| US-20130079323-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | HCAR2 2341/4885XDH 137/4885KMT2A 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.